Shopping Cart 0
Cart Subtotal
USD 0

BioTime Inc (BTX) - Product Pipeline Analysis, 2018 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company's Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company BioTime Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

BioTime Inc Company Overview 5

BioTime Inc Company Snapshot 5

BioTime Inc Pipeline Products and Ongoing Clinical Trials Overview 5

BioTime Inc - Pipeline Analysis Overview 8

Business Description 8

BioTime Inc - Key Facts 8

BioTime Inc - Major Products and Services 9

BioTime Inc Pipeline Products by Development Stage 10

BioTime Inc Ongoing Clinical Trials by Trial Status 12

BioTime Inc Pipeline Products Overview 14

BioTime Films 14

BioTime Films Product Overview 14

BioTime Sponges 15

BioTime Sponges Product Overview 15

Drug Delivery Device - Ankle Fracture 16

Drug Delivery Device - Ankle Fracture Product Overview 16

HyStem - BDNF 17

HyStem - BDNF Product Overview 17

HyStem-Spine 18

HyStem-Spine Product Overview 18

HyStem-Tendon 19

HyStem-Tendon Product Overview 19

PanC-Dx - Colon Cancer 20

PanC-Dx - Colon Cancer Product Overview 20

PanC-Dx - Prostate Cancer 21

PanC-Dx - Prostate Cancer Product Overview 21

ReGlyde 22

ReGlyde Product Overview 22

ReGlyde Drug Delivery Device - Osteoarthritis 23

ReGlyde Drug Delivery Device - Osteoarthritis Product Overview 23

Renevia 24

Renevia Product Overview 24

Renevia Clinical Trial 25

BioTime Inc - Key Competitors 26

BioTime Inc - Key Employees 27

BioTime Inc - Key Employee Biographies 28

BioTime Inc - Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Joint Venture 30

Recent Developments 31

BioTime Inc, Recent Developments 31

Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 31

May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 31

Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 32

Mar 13, 2018: BioTime Submits CE Mark Application for European Approval of Renevia 34

Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 35

Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 35

Jan 29, 2018: Renevia Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference 36

Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 36

Jan 22, 2018: Hologic's Cynosure Division Launches TempSure Envi 37

Jan 22, 2018: BioTime Announces Clinical and Corporate Milestone Targets of Renevia for 2018 37

Appendix 39

Methodology 39

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

BioTime Inc Pipeline Products by Equipment Type 6

BioTime Inc Pipeline Products by Development Stage 10

BioTime Inc Ongoing Clinical Trials by Trial Status 12


List Of Table

List of Tables

BioTime Inc Pipeline Products and Ongoing Clinical Trials Overview 5

BioTime Inc Pipeline Products by Equipment Type 6

BioTime Inc Pipeline Products by Indication 7

BioTime Inc Ongoing Clinical Trials by Trial Status 7

BioTime Inc, Key Facts 8

BioTime Inc, Major Products and Services 9

BioTime Inc Number of Pipeline Products by Development Stage 10

BioTime Inc Pipeline Products Summary by Development Stage 11

BioTime Inc Ongoing Clinical Trials by Trial Status 12

BioTime Inc Ongoing Clinical Trials Summary 13

BioTime Films - Product Status 14

BioTime Films - Product Description 14

BioTime Sponges - Product Status 15

BioTime Sponges - Product Description 15

Drug Delivery Device - Ankle Fracture - Product Status 16

Drug Delivery Device - Ankle Fracture - Product Description 16

HyStem - BDNF - Product Status 17

HyStem - BDNF - Product Description 17

HyStem-Spine - Product Status 18

HyStem-Spine - Product Description 18

HyStem-Tendon - Product Status 19

HyStem-Tendon - Product Description 19

PanC-Dx - Colon Cancer - Product Status 20

PanC-Dx - Colon Cancer - Product Description 20

PanC-Dx - Prostate Cancer - Product Status 21

PanC-Dx - Prostate Cancer - Product Description 21

ReGlyde - Product Status 22

ReGlyde - Product Description 22

ReGlyde Drug Delivery Device - Osteoarthritis - Product Status 23

ReGlyde Drug Delivery Device - Osteoarthritis - Product Description 23

Renevia - Product Status 24

Renevia - Product Description 24

Renevia - A Randomized, Evaluator-blinded, Delayed-treatment-controlled Study of the Effectiveness and Safety of Renevia, A Resorbable Matrix for the Delivery of Autologous Adipose Derived Cells to treat Subcutaneous Facial Lipoatrophy Defects Arising from HIV 25

BioTime Inc, Key Employees 27

BioTime Inc, Key Employee Biographies 28

BioTime Inc, Subsidiaries 29

BioTime Inc, Joint Venture 30

Glossary 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

BioTime Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Noveome Biotherapeutics Inc

B. Braun Melsungen AG

Hospira Inc

Alpha Therapeutic Corp

Geron Corp

Baxter International Inc

Sanofi